Can ischemia-modified albumin be a valuable indicator of tissue ischemia in polycythemia vera?

References

• Michiels JJ, Berneman Z, van Bockstaele D, de Raeve H, Schroyens W. Current diagnostic criteria for the chronic myelo-proliferative disorders essential thrombocythemia, polycythemia vera and chronic idiopathic myelofibrosis. Pathol Biol 2007; 55: 92–104.
   PubMed Web of Science ®Google Scholar
• Messinezy M, Pearson TC. The classification and diagnostic criteria of the erythrocytoses (polycythaemias). Clin Lab Haem 1999; 21: 309–316.
   PubMedGoogle Scholar
• Michiels JJ, Berneman Z, van Bockstaele D, van der Planken M, de Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding com-plications, and the molecular etiology of essential thrombocythe-mia, polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174–207.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. How I treat patients with polycythemia vera.Blood 2007; 109: 5104–5111.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Schroyens W et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006; 17: 528–544.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Barbui T et al. Leukocytosis as a majorthrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446–2452.
   PubMed Web of Science ®Google Scholar
• Spivak JL. Polycythemia vera: myths, mechanisms, and manage-ment. Blood 2002; 100: 4272–4290.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Gisslinger H, Tosetto A et al. Factor V leiden mutationcarriership and venous thromboembolism in polycythemia vera and essential thrombocythaemia. Am J Hematol 2002; 71: 1–6.
   PubMed Web of Science ®Google Scholar
• Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding andischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 2006; 108: 410–411.
   PubMed Web of Science ®Google Scholar
• Apple FS, Wu AH, Mair J et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810–824.
   PubMed Web of Science ®Google Scholar
• Gunduz A, Turedi S, Mentese A et al. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008; 26: 874–878.
   PubMed Web of Science ®Google Scholar
• Roy D, Quiles J, Sharma R et al. Ischemia- modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004; 50: 1656–1660.
   PubMed Web of Science ®Google Scholar
• Gunduz A, Mentese A, Turedi S et al. Serum ischemia- modified albumin increases in critical lower limb ischemia. Emerg Med J 2008; 25: 351–353.
   PubMed Web of Science ®Google Scholar
• Dobrovolsky AB, Titeeva EV. The fibrinolysis system: regulation of activity and phsiologic functions of its main components. Biochemistry 2002; 67: 99–108.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Lau E, Winkler TV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia — a preliminary report. J Emerg Med 2000; 19: 311–315.
   PubMed Web of Science ®Google Scholar
• Schafer AT. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214–4222.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in poly-cythemia vera and essential thrombocythemia. Br J Haematol 2004; 128: 275–290.
   Web of Science ®Google Scholar
• Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Am Soc Hematol 2005: 409–415.
   PubMedGoogle Scholar
• Lugassy G, Filin I. Study of fibrinolytic parameters in different types of polycythemia. Am J Hematol 1999; 60: 196–199.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myelopro-liferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22: 2020–2028.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V. Ischemia-modified albumin: is this marker of ischemia ready for prime time use? Hellenic J Cardiol 2008; 49: 260–266.
   PubMed Web of Science ®Google Scholar
• Wu AH. The ischemia-modified albumin biomarker for myocar-dial ischemia. MLO Meds Lab Obs 2003; 35: 36–40.
   PubMedGoogle Scholar
• Dusec J, St'asek J, Tichy M et al. Prognostic significance of ischemia modified albumin after percutaneous coronary interven-tion. Clin Chim Acta 2006; 367: 77–80.
   PubMed Web of Science ®Google Scholar
• Sinha MK, Roy D, Gaze DC, Collinson and J-C Kaski PO. Role of Ischemia modified albumin', a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29–34.
   PubMed Web of Science ®Google Scholar
• Bhagavan NV, Lai EM, Rios PA et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581–585.
   PubMed Web of Science ®Google Scholar
• Mentese A, Mentese U, Turedi S et al. Effect of deep vein thrombosis on ischemia-modified albumin levels. Emerg Med J 2008; 25: 811–814.
   PubMed Web of Science ®Google Scholar
• Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE. Value of ischemia modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007; 25: 770–773.
   PubMed Web of Science ®Google Scholar
• Rosc D, Kremplewska-Nalezyta E, Gadomska G, Drewniak W, Koczubik W. Plasminogenesis in blood of patients with chronic myeloproliferative syndromes. Pol Arch Med Wewn 2006; 115: 23–28.
   PubMedGoogle Scholar